BAM
HUMA icon

Byrne Asset Management’s Humacyte HUMA Stock Holding History

Byrne Asset Management’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,000
Closed -$8.7K – 589
2025
Q3 		$8.7K Hold
5,000
– – 0.01% 423
2025
Q2 		$10.4K Buy
5,000
+2,000
+67% +$3.84K 0.01% 397
2025
Q1 		$5.13K Hold
3,000
– – ﹤0.01% 466
2024
Q4 		$15.2K Hold
3,000
– – 0.01% 334
2024
Q3 		$16.3K Hold
3,000
– – 0.01% 331
2024
Q2 		$14.1K Hold
3,000
– – 0.01% 330
2024
Q1 		$9.33K Buy
3,000
+1,000
+50% +$3.36K 0.01% 377
2023
Q4 		$5.96K Hold
2,000
– – ﹤0.01% 400
2023
Q3 		$6K Buy
+2,000
New +$6.62K 0.01% 381

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Byrne Asset Management's HUMA Position: Q4 2025 in Review

Byrne Asset Management sold out of Humacyte (HUMA) in Q4 2025, closing a stake of 5,000 shares — an estimated $8.7K sold.

Byrne Asset Management first reported a position in HUMA in Q3 2023 and held it in 9 quarters. The position peaked at $16.3K in Q3 2024. 147 funds tracked by Wall St. Rank hold HUMA as of Q4 2025.

  • Byrne Asset Management reported no remaining Humacyte position as of Q4 2025 after selling out during the quarter.
  • Byrne Asset Management sold 5,000 Humacyte shares in Q4 2025, an estimated $8.7K.
  • Byrne Asset Management first reported a position in Humacyte in Q3 2023 and held it in 9 quarters.
  • Byrne Asset Management's Humacyte position peaked at $16.3K in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Humacyte as of Q4 2025.

Based on Byrne Asset Management's 13F filing for Q4 2025, filed 12 Jan 2026.